Dopamine receptor and serotonin receptor (DR (Dopamine receptor), 5-HT receptor (Serotonin receptor))

**Dopamine receptors** and **serotonin receptors** are two large families of neurotransmitter receptors that mediate the physiological and pharmacological effects of dopamine and serotonin, respectively. Both receptor families are predominantly **G protein-coupled receptors**, except for the 5-HT3 serotonin receptor, which is a ligand-gated ion channel. Multiple receptor subtypes exist: dopamine receptor subtypes include D1, D2, D3, D4, and D5, while serotonin receptor subtypes include 5-HT1 through 5-HT7, each with further subdivisions[1][3][5][9]. These receptors are widely distributed throughout the central and peripheral nervous systems and are involved in regulating a broad range of processes including mood, cognition, reward, movement, and endocrine signaling [1][3][4][6][7]. They are established and highly validated therapeutic targets for various neuropsychiatric and neurological diseases, and are modulated by a wide range of clinically important drugs, including antipsychotics, antidepressants, antiemetics, and drugs of abuse[6][7][8][2]. Their therapeutic targeting is associated with several predictable challenges and safety concerns, many of which stem from their broad distribution and multiple physiological roles[7][8].

Other names

Dopaminergic receptor (for dopamine receptor)5-hydroxytryptamine receptor (for serotonin receptor)5-HT receptor (for serotonin receptor)DA receptor (for dopamine receptor)

Antagonism or partial agonism at specific receptor subtypes (e.g. D2, 5-HT2A)[6][7][8] Modulation of neurotransmitter release Inhibition of reuptake (indirectly modulating receptor activity, e.g. SSRIs, cocaine, MDMA)[2] Activation/inhibition of downstream second messenger pathways (e.g. cAMP production by D1-like receptors)[1][5]